Dissemin is shutting down on January 1st, 2025

Published in

BioMed Central, Trials, 1(14), p. 177

DOI: 10.1186/1745-6215-14-177

Links

Tools

Export citation

Search in Google Scholar

Confronting diversity in the production of clinical evidence goes beyond merely including under-represented groups in clinical trials

Journal article published in 2013 by Karien Stronks ORCID, Nicolien F. Wieringa, Anita Hardon
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

There is increasing evidence that outcomes of health care differ by patient characteristics, such as gender and ethnicity. If evidence-based medicine is to improve quality of care for all patients, it is essential to take this diversity into account when designing clinical studies. So far, this notion has mainly been translated into recommendations for including minority populations in trials. We argue that a more comprehensive view of the production of diversity-sensitive clinical evidence is needed, one that takes heterogeneity as a starting point in research. We call for a mix of methodological approaches aimed at identifying diversity issues that matter and analysing the impact of these diversities on clinical outcomes. Institutional changes are necessary to support this methodological reform.